Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Su-Ann YeohMilena GianfrancescoSaskia Lawson-ToveyKimme L HyrichAnja StrangfeldLaure GossecLoreto CarmonaElsa F MateusMartin SchaeferChristophe RichezEric HachullaMarie HolmqvistAnd Carlo Alberto ScirèHanns-Martin LorenzReinhard E VollRebecca HasseliArundathi JayatillekeTiffany Y-T HsuKristin M D'SilvaVictor Román Pimentel-QuirozMonica Vasquez Del MercadoSamuel Katsuyuki ShinjoEdgard Torres Dos Reis NetoLaurindo Ferreira da Rocha JuniorAna Carolina de Oliveira E Silva MontandonGuillermo J Pons-EstelSofía OrnellaMaria Eugenia D'Angelo ExeniEdson VelozoPaula JordanEmily SirotichJonathan S HausmannJean W LiewLindsay JacobsohnMonique Gore-MassyPaul SufkaRebecca GraingerSuleman BhanaZachary WallacePhilip C RobinsonJinoos YazdanyPedro M Machadonull nullPublished in: RMD open (2022)
This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.
Keyphrases
- coronavirus disease
- sars cov
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- emergency department
- primary care
- juvenile idiopathic arthritis
- respiratory syndrome coronavirus
- physical activity
- adipose tissue
- diffuse large b cell lymphoma
- type diabetes
- metabolic syndrome
- big data
- electronic health record
- hodgkin lymphoma
- community dwelling